TrialInvestigational new drugs2020

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.

Nobuyuki Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.